{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["77"],"submitter":["Gaebe K"],"funding":["Institute for Clinical Evaluative Sciences","Ministry of Long-Term Care","Ministry of Health, Ontario","AstraZeneca","Kementerian Kesihatan Malaysia"],"pubmed_abstract":["<h4>Background</h4>Patients with small cell lung cancer (SCLC) have historically been characterised by poor overall survival (OS) and high risk for brain metastasis (BM), but large-scale real-world evidence on clinical presentation and treatment in this population is lacking. Our aim was to describe the clinical characteristics and outcomes of patients with SCLC and BM in Ontario, Canada.<h4>Methods</h4>This population-based, retrospective cohort study included all patients in Ontario, Canada, who were diagnosed with SCLC between April 1, 2010, and March 31, 2018. Data were analysed between June 2, 2022, and December 20, 2023. Patients with second cancer diagnosis were excluded. Patients were identified and data retrieved from the Institute for Clinical Evaluative Sciences (ICES) databases"],"journal":["EClinicalMedicine"],"pagination":["102871"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11474380"],"repository":["biostudies-literature"],"pubmed_title":["Brain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study."],"pmcid":["PMC11474380"],"pubmed_authors":["Lok BH","Chan KKW","Gaebe K","Das S","Sahgal A","Menjak IB","Chen S","Erickson AW"],"additional_accession":[]},"is_claimable":false,"name":"Brain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study.","description":"<h4>Background</h4>Patients with small cell lung cancer (SCLC) have historically been characterised by poor overall survival (OS) and high risk for brain metastasis (BM), but large-scale real-world evidence on clinical presentation and treatment in this population is lacking. Our aim was to describe the clinical characteristics and outcomes of patients with SCLC and BM in Ontario, Canada.<h4>Methods</h4>This population-based, retrospective cohort study included all patients in Ontario, Canada, who were diagnosed with SCLC between April 1, 2010, and March 31, 2018. Data were analysed between June 2, 2022, and December 20, 2023. Patients with second cancer diagnosis were excluded. Patients were identified and data retrieved from the Institute for Clinical Evaluative Sciences (ICES) databases","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T19:30:58.972Z","creation":"2025-04-04T23:50:02.812Z"},"accession":"S-EPMC11474380","cross_references":{"pubmed":["39416386"],"doi":["10.1016/j.eclinm.2024.102871"]}}